TUmeurs THYroïdiennes REFractaires.

Publication du réseau

Art.1

Art.1

9 avril 2019

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.

Art.2

Art.2

9 avril 2019

Cabozantinib: Mechanism of action, efficacy and indications. 2. Cochin V, Gross-Goupil M, Ravaud A, Godbert Y, Le Moulec S 2017 Bulletin du cancer 104:393-401.

Art.3

Art.3

9 avril 2019

Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases. 3. Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannee G, Criniere L, Do Cao...

Art.4

Art.4

9 avril 2019

Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients 4. Atallah V, Hocquelet A, Do Cao C, Zerdoud S, De...

Art.5

Art.5

9 avril 2019

Restoring Radioiodine Uptake in BRAF V600E-Mutated Papillary Thyroid Cancer. 5. Huillard O, Tenenbaum F, Clerc J, Goldwasser F, Groussin L 2017 Journal of the Endocrine Society 1:285-287.

Art.6

Art.6

9 avril 2019

Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. 6. Paepegaey AC, Cochand-Priollet B, Louiset E, Sarfati PO, Alifano M, Burnichon...

 Art.7

Art.7

9 avril 2019

DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. 7. Buffet C, Hecale-Perlemoine K, Bricaire L, Dumont F, Baudry...

Art.8

Art.8

9 avril 2019

Next Generation Sequencing and Association Studies in Familial Nonmedullary Thyroid Carcinoma: Let's Choose Appropriate Controls. 8. Cazabat L, Terray A, de Mazancourt P, Ropers J, Groussin L, Raffin-Sanson ML 2017...

Art.9

Art.9

9 avril 2019

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. 9. Ravaud A, de...

Art.10

Art.10

9 avril 2019

Development of Photoonycholysis with Vandetanib Therapy. 10. Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, Sibaud V 2017 Skin appendage disorders 2:146-151.

Art.11

Art.11

9 avril 2019

Galectin-1 is a diagnostic marker involved in thyroid cancer progression. 11. Arcolia V, Journe F, Wattier A, Leteurtre E, Renaud F, Gabius HJ, Remmelink M, Decaestecker C, Rodriguez A, Boutry...

Art.12

Art.12

9 avril 2019

Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine. 12. Barbolosi D, Summer I, Meille C, Serre R, Kelly A, Zerdoud S, Bournaud C,...

 Art.13

Art.13

9 avril 2019

The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. 13. Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D,...

Art.14

Art.14

9 avril 2019

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. 14. Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E,...

Art.15

Art.15

9 avril 2019

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Annals of oncology 15. Schlumberger M, Elisei R, Muller S, Schoffski...

Art.16

Art.16

9 avril 2019

NADPH Oxidase NOX4 Is a Critical Mediator of BRAF(V600E)-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. 16. Azouzi N, Cailloux J, Cazarin JM, Knauf JA, Cracchiolo J, Al...

Art.17

Art.17

9 avril 2019

Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation. 17. Bennaceur-Griscelli A, Hadoux J, Feraud...

Art.18

9 avril 2019

Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. 18. Hadoux J, Schlumberger M 2017 Best practice & research Clinical endocrinology & metabolism 31:335-347.

Art.19

Art.19

9 avril 2019

La Revue du praticien 19. Schlumberger M, Berdelou A, Leboulleux S 2017, 67:685-688.

Art.20

Art.20

9 avril 2019

Timing of multikinase inhibitor initiation in differentiated thyroid cancer. 20. Brose MS, Smit J, Lin CC, Pitoia F, Fellous M, DeSanctis Y, Schlumberger M, Tori M, Sugitani I 2017 Endocrine-related...

Art.21

Art.21

9 avril 2019

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. 21. Schmidt A, Iglesias L, Klain M, Pitoia F, Schlumberger MJ 2017  Archives of endocrinology and metabolism 61:81-89.

Art.22

Art.22

9 avril 2019

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. 22. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah...

Art.23

Art.23

9 avril 2019

18F-DOPA PET/CT in Orbital Metastasis From Medullary Thyroid Carcinoma. 23. Ruiz JB, Orre M, Cazeau AL, Henriques de Figueiredo B, Godbert Y 2016 Clinical nuclear medicine 41:e296-297.

Art.24

Art.24

9 avril 2019

23 Lung Metastases Treated by Radiofrequency Ablation Over 10 Years in a Single Patient: Successful Oncological Outcome of a Metastatic Cancer Without Altered Respiratory Function. 24. Crombe A, Buy X,...

Art.25

Art.25

9 avril 2019

Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. Journal of clinical oncology. 25. Godbert Y, Henriques de Figueiredo B, Bonichon F, Chibon F, Hostein I,...

Art.26

Art.26

9 avril 2019

Vemurafenib for BRAF(V600E)-positive metastatic papillary thyroid cancer. 26. Huillard O, Tenenbaum F, Clerc J, Goldwasser F, Groussin L 2016 The Lancet Oncology 17:e468.

Art.27

Art.27

9 avril 2019

 Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. Journal of nuclear medicine Immuno-PET Using 27. Bodet-Milin...

Art.28

Art.28

9 avril 2019

Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study. 28. Chereau N, Giudicelli X, Pattou F,...

Art.29

Art.29

9 avril 2019

Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery. 29. Segura D, Dupuis C, Chabre O, Piolat C,...

 Art.30

Art.30

9 avril 2019

MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. 30. Lassalle S, Zangari J, Popa A, Ilie M, Hofman V, Long E, Patey M, Tissier F, Belleannee G, Trouette...

Art.31

Art.31

9 avril 2019

Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse. 31. Compagnon F, Zerdoud S, Rives M, Laprie A, Sarini J, Grunenwald S, Chaltiel L, Graff...

Art.32

Art.32

9 avril 2019

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study. 32. de la Fouchardiere C, Oussaid N, Derbel O, Decaussin-Petrucci M,...

Art.34

Art.34

9 avril 2019

Lenvatinib in radioiodine refractory thyroid carcinomas De la Fouchardiere C 2016 Bulletin du cancer 103:905-910.

Art.35

Art.35

9 avril 2019

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. 35. Sherman SI, Clary DO, Elisei R, Schlumberger...

 Art.36

Art.36

9 avril 2019

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. 36. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW,...

Art.37

Art.37

9 avril 2019

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. 37. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH,...

Art.38

Art.38

9 avril 2019

Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. 38. Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A,...

Art.39

Art.39

9 avril 2019

Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation. 39. Hadoux J, Feraud O, Griscelli F, Opolon...

Art.40

Art.40

9 avril 2019

NADPH oxidases: new actors in thyroid cancer? 40. Ameziane-El-Hassani R, Schlumberger M, Dupuy C 2016  Nature reviews Endocrinology 12:485-494.

 Art.41

Art.41

9 avril 2019

Composite Mucoepidermoid Carcinoma and Columnar Cell Variant of Papillary Carcinoma of the Thyroid: A Case Report and Review of the Literature. 41. Taconet S, Bosq J, Hartl D, Schlumberger M,...

Art.42

Art.42

9 avril 2019

Management of advanced medullary thyroid cancer. 42. Hadoux J, Pacini F, Tuttle RM, Schlumberger M 2016 The lancet Diabetes & endocrinology 4:64-71.

Art.43

Art.43

9 avril 2019

Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. 43. Wassermann J, Bernier MO, Spano JP, Lepoutre-Lussey C, Buffet C, Simon JM, Menegaux F, Tissier F, Leban M, Leenhardt...

Art.44

9 avril 2019

PET/Computed Tomography and Thermoablation (Radiofrequency, Microwave, Cryotherapy, Laser Interstitial Thermal Therapy). 44. Bonichon F, Godbert Y, Gangi A, Buy X, Palussiere J 2015 PET clinics 10:519-540.

Art.45

Art.45

9 avril 2019

Local treatment of metastases from differentiated thyroid cancer. 45. Bonichon F, Buy X, Godbert Y, Pointillart V, Henriques de Figueiredo B, Gangi A, Palussiere J 2015  Annales d'endocrinologie 76:1S40-46.

Art.46

Art.46

9 avril 2019

Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer. 46. Cazzato RL, Bonichon F, Buy X, Godbert Y, de Figuereido BH, Pointillart...

Art.47

Art.47

9 avril 2019

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 47. Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C,...

 Art.48

Art.48

9 avril 2019

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. 48. Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y,...

Art.49

9 avril 2019

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter. Clinical cancer research 49. Huillard O, Tenenbaum F, Clerc J, Goldwasser F, Groussin L 2015  official journal of the...

Art.50

Art.50

9 avril 2019

Buffet C, Groussin L 2015 Molecular perspectives in differentiated thyroid cancer. Annales d'endocrinologie 76:1S8-15.

Art.52

Art.52

9 avril 2019

Dual Specificity Phosphatase 5, a Specific Negative Regulator of ERK Signaling, Is Induced by Serum Response Factor and Elk-1 Transcription Factor. 52. Buffet C, Catelli MG, Hecale-Perlemoine K, Bricaire L,...

Art.53

Art.53

9 avril 2019

Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients. 53. Brient C, Mucci S, Taieb D, Mathonnet M, Menegaux F, Mirallie E, Meyer P,...

 Art.54

Art.54

9 avril 2019

Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. 54. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl...

Art.55

Art.55

9 avril 2019

Thyroid cancers: from epidemiology to molecular biology 55 Lalmi F, Sadoul JL, Rohmer V 2015  Annales d'endocrinologie 76:S19-28.

Art.56

Art.56

10 avril 2019

(18)F-Fluorine-18-l-dihydroxyphenylalanine ((18)F-DOPA) positive isolated peritoneal carcinomatosis from a MENII-related medullary thyroid carcinoma. About an atypical metastatic site and utility of (18)F-FDOPA. 56. Aziz AL, Dierickx L, Courbon F, Taieb D,...

Art.57

Art.57

10 avril 2019

Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases. 57. Le Pennec S, Konopka T, Gacquer D, Fimereli D, Tarabichi M, Tomas G, Savagner F,...

Art.58

Art.58

10 avril 2019

Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer. 58. Do Cao C, Wemeau JL 2015 Annales d'endocrinologie 76:1S47-52.

Art.59

Art.59

10 avril 2019

[Thyroid pathology. Case No. 5: Poorly differentiated thyroid carcinoma] 59. Leteurtre E 2015. Annales de pathologie 35:413-418.

Art.60

Art.60

10 avril 2019

Targeted treatments of radio-iodine refractory differentiated thyroid cancer. 60. de la Fouchardiere C 2015 Annales d'endocrinologie 76:1S34-39.

Art.61

Art.61

10 avril 2019

American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 61....

ART.62

ART.62

10 avril 2019

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. 62. Wells SA, Jr., Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A,...

Art.63

Art.63

10 avril 2019

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. 63. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y,...

Art.64

Art.64

10 avril 2019

Lenvatinib in radioiodine-refractory thyroid cancer. 64. Schlumberger M, Tahara M, Wirth LJ 2015 The New England journal of medicine 372:1868.

Art.65

Art.65

10 avril 2019

Not Available. 65. Schlumberger M 2015 Bulletin de l'Academie nationale de medecine 199:1395-1407.

Art.66

Art.66

10 avril 2019

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. 66. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG,...

Art.67

Art.67

10 avril 2019

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. 67. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini...

Art.68

Art.68

10 avril 2019

NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. 68. Ameziane-El-Hassani R, Talbot M, de Souza Dos Santos MC, Al Ghuzlan A, Hartl D, Bidart...

Art.51

Art.51

10 avril 2019

Sorafenib for patients with differentiated thyroid cancer. 51. Huillard O, Blanchet B, Durand JP, Goldwasser F 2015 Lancet (London, England) 385:227.

Art.70

Art.70

10 avril 2019

(18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. 70. Levy A, Leboulleux S, Lepoutre-Lussey C, Baudin E, Ghuzlan AA, Hartl D, Deutsch E, Deandreis...

Il n'y a aucun article dans cette catégorie. Si des sous-catégories sont affichées sur cette page, elles peuvent contenir des articles.

 

En visitant notre site Web, vous acceptez que nous utilisions des cookies pour vous assurer d'obtenir la meilleure expérience.